A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies

BACKGROUND: There is a lack of molecular markers that effectively predict response to treatment with immune checkpoint inhibitors in patients with uroepithelial bladder carcinoma. The purpose of this study was to explore molecular markers that effectively predict the efficacy of Atezolizumab in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chunlei, Kang, Yindong, Miao, Pengcheng, Chang, Dehui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493780/
https://www.ncbi.nlm.nih.gov/pubmed/37701107
http://dx.doi.org/10.21037/tcr-23-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493780/
https://www.ncbi.nlm.nih.gov/pubmed/37701107
http://dx.doi.org/10.21037/tcr-23-220

Ejemplares similares